Trypsin activates proteinase-activated receptor-2 (PAR 2 ) by a mechanism that involves the release of a tethered receptoractivating sequence. We have identified two peptides, FS-LLRY-NH 2 (FSY-NH 2 ) and LSIGRL-NH 2 (LS-NH 2 ) that block the ability of trypsin to activate PAR 2 either in PAR 2 -expressing Kirsten virus-transformed kidney (KNRK) cell lines or in a rat aorta ring preparation. The reverse PAR 2 peptide, LRGILS-NH 2 (LRG-NH 2 ) did not do so and FSY-NH 2 failed to block thrombin activation of PAR 1 in the aorta ring or in PAR 1 -expressing human embryonic kidney cells. Half-maximal inhibition (IC 50 ) by FSY-NH 2 and LS-NH 2 of the activation of PAR 2 by trypsin in a PAR 2 KNRK calcium-signaling assay was observed at about 50 and 200 M, respectively. In contrast, the activation of PAR 2 by the PAR 2 -activating peptide, SLIGRL-NH 2 (SL-NH 2 ) was not inhibited by FSY-NH 2 , LS-NH 2 , or LRG-NH 2 . In a casein proteolysis assay, neither FSY-NH 2 nor LS-NH 2 inhibited the proteolytic action of trypsin on its substrate. In addition, FSY-NH 2 and LS-NH 2 were unable to prevent trypsin from hydrolyzing a 20-amino acid peptide, GPNSKGR/SLIGRLDTPYGGC representing the trypsin cleavage/activation site of rat PAR 2 . Similarly, FSY-NH 2 and LS-NH 2 failed to block the ability of trypsin to release the PAR 2 N-terminal epitope that is cleaved from the receptor upon proteolytic activation of receptor-expressing KNRK cells. We conclude that the peptides FSY-NH 2 and LS-NH 2 block the ability of trypsin to activate PAR 2 by a mechanism that does not involve a simple inhibition of trypsin proteolytic activity, but possibly by interacting with a tethered ligand receptor-docking site.
The serine proteinase, trypsin, that acts as a digestive enzyme can also regulate target tissues via the proteolytic activation of a G-protein coupled proteinase-activated receptor, PAR 2 (Nystedt et al., 1994 : Dery et al., 1998 . PAR 2 activation by trypsin, like the activation of PAR 1 by thrombin, involves the proteolytic unmasking of an amino terminal receptor sequence that acts as a tethered ligand (Vu et al., 1991) . As was discovered for the related thrombin-activated receptor PAR 1 (Vu et al., 1991) , for PAR 2 short synthetic peptides based on the proteolytically revealed tethered ligand sequence, beginning with serine in rat (SLIGRL-NH 2 ) and human (SLIGKV-NH 2 ) PAR 2 , can on their own activate PAR 2 , so as to mimic the action of trypsin in a variety of tissues and cultured cells (Nystedt et al., 1994; Al-Ani et al., 1995; Hollenberg et al., 1997; . In addition, the peptide, SFLLR-NH 2 , based on the proteolytically revealed human PAR 1 tethered ligand that activates PAR 1 , was also found to activate PAR 2 , whereas the partial reverse PAR 1 and PAR 2 -derived peptide sequences, FS-LLRY-NH 2 (FSY-NH 2 ) and LSIGRL-NH 2 (LS-NH 2 ) failed to activate the PAR 2 receptor (Blackhart et al., 1996; Al-Ani et al., 1999b) . In the past, a peptide, YFLLRNP, derived from the tethered ligand sequence of human PAR 1 , was found to be a partial PAR 1 receptor agonist, able to antagonize the action of thrombin in human platelets (Rasmussen et al., 1993) , but not in cultured human endothelial cells (Kruse et al., 1995) . To date, there is no available PAR 2 antagonist. Given the crossreactivity of PAR 1 -derived peptides with PAR 2 , we hypothesized that peptide analogs based on either the PAR 1 or PAR 2 -derived tethered ligand might be able to act as antagonists for the PAR 2 receptor, in keeping with the ability of YFLLRNP to antagonize PAR 1 (Rasmussen et al., 1993) . To test this hypothesis, we synthesized peptide sequences based on the tethered ligands of PAR 1 and PAR 2 , as described above, with a reverse sequence of the first two amino acids (i.e., FSLLRY-NH 2 and LSIGRL-NH 2 ). These two peptides were evaluated for their ability to act as PAR 2 antagonists for either trypsin or SLIGRL-NH 2 with a calcium signaling assay method employing rat and human PAR 2 -transfected cell lines AlAni et al., 1999a,b) and an endothelium-dependent rat aorta relaxation assay .
Materials and Methods
PAR 2 Cloning and Expression. Based on the previously determined rat PAR 2 sequence (Saifeddine et al., 1996) and in keeping with our previous work (Al-Ani et al., 1999a,b) rat kidney cDNA was prepared using the first-strand cDNA synthesis kit (Pharmacia LKB Biotechnology, Uppsala, Sweden) according to manufacturer's recommendations at 37°C for 60 min; 3 l of this solution was used for polymerase chain reaction (PCR) amplification to prepare a fulllength receptor cDNA with primer pairs flanking the entire coding region, designed on the basis of the published rat PAR 2 sequence (Saifeddine et al., 1996) . The primer pairs were: forward primer, PAR 2 -F: (containing a HindIII site and Kozak sequence shown in bold), 5Ј TCAAGCTTCCACCATGCGAAGTCTCAGCCTGGC 3Ј and reverse primer, PAR 2 R: (containing SmaI site shown in bold) 5Ј CCCGGGCTCAGTAGGAGGTTTTAACAC3Ј. Routinely, amplification was done using 2.5 units of Taq DNA polymerase (Promega, Madison, WI) in a 10 mM Tris-HCl buffer, pH 9.0 (50 l, final volume) containing 1.5 mM MgCl 2 , 50 mM KCl, 0.1% (v/v) Triton X-100, and 0.2 mM concentration of each dNTPs. Amplification was allowed to proceed for 35 cycles beginning with a 1-min denaturing period at 94°C, followed by a 1-min reannealing time at 55°C, and a primer extension period of 2 min at 72°C. The PCR products were separated by 1.5% agarose gel electrophoresis and visualized with ethidium bromide. The PCR product was "gene-cleaned" (Magic PCR Preps DNA purification system; Promega) and ligated (Ready To Go T4 ligase; Amersham Biosciences AB, Uppsala, Sweden) into the PGEM-T vector (Promega). Two microliters of this ligation mixture was used to transform Escherichia coli strain DH5␣ to produce permanent clones for both manual and automated sequencing by the dideoxynucleotide chain termination method (Sanger et al., 1977) , employing a T7 DNA sequencing kit (Amersham Biosciences, Piscataway, NJ) or via the DNA Services Facility at the University of Calgary Faculty of Medicine. Then, the rat PAR 2 cDNA was further subcloned into the pcDNA3 mammalian expression vector (Invitrogen, Carlsbad, CA). Rat PAR 2 was then transfected into Kirsten virus-transformed rat kidney (KNRK) cells (American Type Culture Collection, Manassas, VA). Cells were transfected using the LipofectAMINE method, according to the manufacturer's instructions (Invitrogen) with 5 g of each construct used per KNRK cell monolayer (60-mm 2 flask, 50 -70% confluent). Transfected cells (either vector alone or PAR 2 -containing vector) were subcloned in geneticincontaining medium (0.6 mg/ml), and PAR 2 -expressing cells were isolated by fluorescence-activated cell sorting with the use of the anti-receptor B5 antibody (Al-Ani et al., 1999b) for rat PAR 2 , to yield permanent cell lines in which Ͼ95% of the populations were found to exhibit reactivity with the antibody. Cells were routinely propagated in genecitin (0.6 mg/ml)-containing Dulbecco's modified Eagle's medium supplemented with 5% (v/v) fetal calf serum, using 80 cm 2 plastic T-flasks. Cells were subcultured by resuspension in calciumfree isotonic saline/EDTA solution, without the use of trypsin. A human PAR 2 construct (Bohm et al., 1996) , kindly provided by Dr. N. Bunnett (University of California, San Francisco, CA) was transfected into KNRK cells as described above for rat PAR 2 .
Measurement of Calcium Signaling Using Fluorescence Emission. Cells to be used for measurements of trypsin and peptidestimulated fluorescence emission (reflecting an increase in intracellular calcium) were grown at 37°C in 80 cm 2 T-flasks under an atmosphere of 5% CO 2 in room air to about 85% confluency and were disaggregated with calcium-free isotonic phosphate-buffered saline containing 0.2 mM EDTA. Either KNRK cells (wild-type, vectortransfected, or PAR 2 -transfected cell lines, as above) or human embryonic kidney (HEK) cells (endogenously expressing both PAR 1 and PAR 2 ) were used essentially according to previously described procedures (Kawabata et al., 1999) . Disaggregated cells were pelleted by centrifugation and resuspended in 1 ml Dulbecco's modified Eagle's medium/10% fetal calf serum for loading with the intracellular calcium indicator, Fluo-3 (Molecular Probes Inc., Eugene, OR) at a final concentration of 22 M (25 g ml
Ϫ1
) of Fluo-3 acetoxymethyl ester. Indicator uptake was established in the presence of 0.25 mM sulfinpyrazone, over 20 to 25 min at room temperature, after which time cells were washed twice by centrifugation and resuspension with the buffer described below, to remove excess dye. Fluo-3 loaded cells were then resuspended to yield a stock solution (about 6 ϫ 10 6 cells ml Ϫ1 ) in a buffer (pH 7.4) of the following composition: 150 mM NaCl, 3 mM KCl, 1.5 mMCaCl 2 , 20 mM HEPES, 10 mM glucose, and 0.25 mM sulfinpyrazone. Fluorescence measurements, reflecting elevations of intracellular calcium, were conducted at 24°C using a PerkinElmer fluorescence spectrometer (PerkinElmer Instruments, Norwalk, CT) with an excitation wavelength of 480 nm and an emission recorded at 530 nm. Cells (about 2 ml of approximately 3 ϫ 10 5 cells ml Ϫ1 ) were maintained in suspension in a stirred (magnetic flea bar) thermostated plastic cuvette (total volume, 4 ml) and peptide or trypsin stock solutions were added directly to the suspension to monitor agonist-induced changes in fluorescence. The fluorescence signals caused by the addition of test agonists (trypsin or PAR 2 APs) were compared with the fluorescence peak height yielded by replicate cell suspensions treated with 2 M ionophore A23187 (Sigma Chemical Co., St. Louis, MO). This concentration of A23187 was at the plateau of its concentration-response curve for a fluorescence response. In this assay, KNRK cells expressing either rat or human PAR 2 yield a robust calcium signal in response to 10 nM trypsin and 10 M SLIGRL-NH 2 , whereas vector-transfected cells lacking PAR 2 do not respond. Measurements were done using three or more replicate cell suspensions derived from two or more independently grown crops of cells. Values in the figure represent the average Ϯ S.E.M. (bars).
Bioassay Procedure. The endothelium-intact rat aorta ring assay used to monitor PAR 2 activation was essentially the same as the one used previously to evaluate the actions of PAR 2 -activating peptides (Al-Ani et al., 1995; Hollenberg et al., 1997) . Male albino Sprague-Dawley rats (250 to 300 g), cared for in accordance with the guidelines of the Canadian Council on animal care, were sacrificed by cervical dislocation and were immediately anticoagulated by the injection of heparin (1000 units in 2 ml of isotonic saline) into the left ventricular circulation. Clot-free portions of aorta were dissected free of adhering tissue and endothelium-intact ring preparation (approximately 2 mm ϫ 2 mm) were cut for use in the bioassay. Aorta ring tissue was equilibrated for 1 h at 37°C in a gassed (5% CO 2 , 95% O 2 ) Krebs-Henseleit buffer, pH 7.4, of the following composition: 118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl 2 , 1.2 mM MgCl 2 , 25 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , and 10 mM glucose. As previously described (AlAni et al., 1995) , the relaxant actions of the PAR 2 -activating peptide (PAR 2 AP) SLIGRL-NH 2 , and trypsin (10 nM) at a concentration that does not activate PAR 1 (Vu et al., 1991) were measured in endothelial-intact rat aorta rings that were preconstricted with 1 M phenylephrine. The presence of an intact endothelium was verified by monitoring relaxant response to 1 M acetylcholine. Agonists and peptide antagonists were added directly to the organ bath (4-ml cuvette) and ring tension was monitored using either Grass or Statham force-displacement transducers.
Assay of Proteolytic Activity of Trypsin. The universal protease substrate, resorufin-labeled casein, was used to detect trypsin proteolytic activity, according to the manufacturer's instructions (Roche Molecular Biochemicals, Summerville, NJ). In brief, 10 nM trypsin was incubated at 37°C for 10 to 60 min with the substrate The absorbance of the released resorufin, reflecting proteolytic activity, was measured using a Beckman DU 640B Spectrophotometer (Beckman Coulter, Inc., Fullerton, CA) at 574 nm.
Measurement of the Proteolytic Release by Trypsin of a PAR 2 -Activating Peptide from an Inactive Synthetic Peptide
Precursor. The peptide sequence: GPNSKGR/SLIGRLDTP-YGGC (P20) represents the trypsin cleavage (site denoted by /) -activation site (active tethered ligand shown in bold) of rat PAR 2 . The sequence YGGC was added for radiolabeling and cysteine-linked protein conjugation. After trypsin cleavage, the sequence, SLIGRLDTP. . . . becomes a receptor activating ligand. P20 itself does not activate PAR 2 . The ability of trypsin (2 nM) to release the receptor-activating sequence, SLIGRLDTP from P20 in the absence or presence of other peptides (FSLLRY-NH 2 , LSIGRL-NH 2 : each at 200 M) was tested using the following protocol. First, trypsin (2 nM) in the absence or presence of 200 M FSLLRY-NH 2 or LSIGRL-NH 2 was incubated with P20 (20 M) for 3 min at room temperature, at which point the proteolytic reaction was quenched by supplementing the solution with added soya trypsin inhibitor (STI: l g ml Ϫ1 ). One minute thereafter, the STI-quenched reaction mixture was added to an indicator suspension of rat PAR 2 -expressing KNRK cells that had been loaded with fluo-3 for monitoring PAR 2 -induced elevations of intracellular calcium, according to the method described above. The generation of a calcium signal (E 530 ) by trypsin treatment of P20, followed by the addition of STI, indicated the successful unmasking by trypsin cleavage of the receptor-activating sequence (SLIGRLDP. . . ) from P20. The calcium signal (E 530 ) response of the cells to the trypsin-cleaved P20 product was expressed as a percentage (% trypsin) of the calcium signal observed in response to 2 nM trypsin that had not been incubated either with peptides or STI. As a control, STI (l g ml
Ϫ1
) was added to the peptide substrate solution prior to the addition of trypsin, in which case no subsequent calcium signal was generated, indicating a lack of P20 cleavage.
Peptides and Other Reagents. All peptides were synthesized by solid-phase methods at the peptide synthesis facility, University of Calgary, Faculty of Medicine (Calgary, AB, Canada; director, Dr. Denis McMaster). High-performance liquid chromatography analysis, mass spectral analysis, and quantitative amino acid analysis confirmed the composition and purity of all peptides. Stock solutions, prepared in 25 mM of HEPES buffer, pH 7.4, were standardized by quantitative amino acid analysis to verify peptide concentration and purity. Porcine trypsin (14,900 units mg Ϫ1 ) was obtained from Sigma Chemical Co. A maximum specific activity of 20,000 units mg Ϫ1 was used to calculate the approximate molar concentration of trypsin in the incubation medium (1U ml Ϫ1 Х 2 nM). Human thrombin (3186 units/mg protein) was from Calbiochem (San Diego, CA); a concentration of 1 unit/ml was calculated to be approximately 10 nM.
Monitoring Trypsin Removal of the PAR 2 N-terminal Epitope in Intact Cells by Immunocytochemistry. The rat PAR 2 clone used for the receptor-expressing KNRK cell line possesses an N-terminal sequence that is proximal to the receptor's cleavage/activation sequence and that is therefore released from the cell upon trypsin activation of PAR 2 . We generated a rabbit antiserum (SLAW) targeted to an antigenic epitope (SLAWLLGGPN-SKGR-GGYGGC) (epitope represented by bold) in the proteinasereleased sequence. The polyclonal antiserum (SLAW) was raised in rabbits as described elsewhere (Kong et al., 1997; Al-Ani et al., 1999b ) for a B5 anti-PAR 2 polyclonal antibody used by us previously (Kong et al., 1997; Al-Ani et al., 1999b) . The B5 antiserum recognizes the PAR 2 receptor cleavage/activation sequence (GPNSKGRSLI-GRLDTP) and can recognize both the cleaved/activated receptors as well as the uncleaved receptor. Neither the B5 nor the SLAW antibodies react with KNRK cells transfected with vector alone and the reactivity of both antibodies with PAR 2 -expressing KNRK cells was abolished by preabsorption with the immunizing peptide (e.g., see Al-Ani et al., 1999b for B5 antibody and Fig. 7) .
The SLAW antiserum was employed with an immunohistochemical approach to demonstrate a loss of the N-terminal precleavage epitope upon proteolytic activation of PAR 2 (Compton et al., 2001) . PAR 2 -expressing cells bearing the N-terminal epitope were or were not treated with trypsin (10 nM) in the absence or presence of FSLLRY-NH 2 (200 M) for 3 min at room temperature at which time soya trypsin inhibitor (1 g/ml) was added to terminate proteolysis. Cell surface epitope was then detected using cytospins of treated cells, prepared with a Shandon cytopsin (Shandon Scientific, Cheshire, England) followed by fixation with 95% ethanol. Cell surface receptor was visualized with a 3,3Ј-diaminobenzidine substrate immunocytochemistry protocol utilized by us previously and described in detail elsewhere (Saifeddine et al., 2001) . The removal of the N-terminal epitope by trypsin was visualized by a disappearance of cell surface reactivity with the SLAW antibody; receptor cleaved at the cell surface, but internalized in the trypsin-treated cells was detected with the B5 antiserum. (SL-NH 2 , 3 M) . Also, at a higher concentration (400 M), FSY-NH 2 and LS-NH 2 failed to cause significant inhibition of the calcium signal triggered by 3 M SL-NH 2 (data not shown). The concentrations of trypsin and SL-NH 2 used were at the EC 50 concentrations of their respective concentration-effect curves, causing a calcium signal equivalent to that of the test ionophore, A23187 (2 M, Fig. 1 , right-hand tracings) (Vergnolle et al., 1998 and data not shown). In addition, calcium responses were not detected in response to trypsin (20 nM) or SL-NH 2 (50 M) either in the "empty" vector-transfected KNRK cell line or in a nontransfected background KNRK cell line (Al-Ani et al., 1999b and data not shown).
Results

FSLLRY-NH
To assess the relative potencies with which FSY-NH 2 and LS-NH 2 were able to inhibit the trypsin-activated PAR 2 signal for both rat and human PAR 2 , concentration-inhibition measurements were done for increasing concentrations of the inhibitor peptides at a constant concentration of trypsin (2 nM for rat PAR 2 ; 10 nM for human PAR 2 ; Fig. 2 ). In the assay, the inhibitory potency of FSY-NH 2 (IC 50 Х 50 M) was about 4-fold greater than that of LS-NH 2 (IC 50 Х 200 M).
We next wanted to investigate whether the PAR 1 derived peptide (FSLLRY-NH 2 ) was able to block thrombin-induced cellular responses via PAR 1 , similar to the above demonstrated inhibition of trypsin-induced activation of PAR 2 . The HEK 293 cell line that expresses both functional PAR 1 and PAR 2 (Kawabata et al., 1999 ) was used to test this hypothesis. In the HEK cells, thrombin activates only PAR 1 , whereas trypsin, at concentrations lower than 25 nM, activates only PAR 2 (Kawabata et al., 1999) . In the absence of FSY-NH 2 peptide, trypsin caused a robust calcium signal via PAR 2 activation in the same cell suspension that had previously responded to thrombin (Fig. 3A) . The response to trypsin was the same as in cells that had not been previously activated by thrombin (data not shown). As shown in Fig. 3B , the addition of FSY-NH 2 (200 M) failed to prevent thrombin (20 nM) from activating PAR 1 . In contrast, the peptide blocked the activation of PAR 2 by trypsin in the same cell suspension that had responded to thrombin (Fig. 3B) .
FSLLRY-NH 2 and LSIGRL-NH 2 Blocked the Relaxant Action of Trypsin but Not SLIGRL-NH 2 in the Aorta Ring Bioassay. In view of the ability of FSY-NH 2 and LS-NH 2 to block trypsin-mediated calcium signaling in human and rat PAR 2 expressing KNRK cells, we hypothesized that in the rat aorta bioassay, the peptides might also block the relaxant action of trypsin, which is mediated via endothelial PAR 2 (Al-Ani et al., 1995; Saifeddine et al., 1996) . As shown in Fig. 4 , the relaxant action of trypsin, at a concentration (1 nM), well below that which might activate PAR 1 , was essentially eliminated in the presence of 200 M FSY-NH 2 , whereas the relaxant action of the PAR 2 -activating peptide, SL-NH 2 , was not affected (Fig. 4A) . At a concentration of 400 M, LS-NH 2 reduced the relaxant effect of trypsin by about 50% (Fig. 4B ), but like FSY-NH 2 , had no effect on relaxation caused by SL-NH 2 (data not shown). In addition, there was no inhibition of the relaxant action of thrombin (200 nM) by 200 M of the peptide FSY-NH 2 (Fig. 4C ). This concentration of FSY-NH 2 markedly suppressed the response Fig. 2 . Concentration-effect curves for the inhibition by FSY-NH 2 and LS-NH 2 of trypsin-mediated calcium signaling in PAR 2 -KNRK cells. Rat PAR 2 -KNRK (A) and human PAR 2 -KNRK (B) cells loaded with fluo-3 as outlined under Materials and Methods were or were not treated with increasing concentrations of either FSY-NH 2 (f) or LS-NH 2 (Ⅺ), and a response to added trypsin (2 nM for rat PAR 2 -KNRK; 10 nM for human PAR 2 -KNRK) was then measured. Data points represent the mean (Ϯ S.E.M., bars) for three or more independent experiments done with triplicate cell suspensions. The responses of peptide-treated cell suspensions were expressed as a percentage (% control) of the control response to trypsin in the absence of added antagonist peptide. No antagonism was observed for the reverse PAR 2 -activating peptide, LRGILS-NH 2 (छ, LRG-NH 2 , upper curve). Fig. 4C ) in a preparation that had previously responded to thrombin. In the absence of FSY-NH 2 , the relaxant response to trypsin in a preparation that had been previously activated by thrombin (right-hand tracing, Fig. 4C ) was the same as in a preparation that had not been previously exposed to thrombin (middle tracing, Fig.  4C ). Activation of PAR1 by lower concentrations of thrombin (50 or 100 nM) was similarly not affected by 200 M FSY-NH 2 (data not shown). The histograms in Fig. 4D summarize the actions of FSY-NH 2 and LS-NH 2 on the function of the proteases, trypsin and thrombin. Since FSY-NH 2 failed to inhibit thrombin action, the action of LS-NH 2 was not tested.
The Proteolytic Activity of Trypsin Is Not Affected by FSLLR-NH 2 and LSIGRL-NH 2 . One key issue to consider was that the ability of FSY-NH2 and LS-NH 2 to affect the activation of PAR 2 by trypsin might be due simply to an inhibitory action on the proteolytic activity of trypsin (e.g., see Bhattacharya et al., 2001 ). This possibility was tested in three ways. First, the ability of FSY-NH 2 and LS-NH 2 to reduce the proteolytic activity of trypsin was tested in a nonspecific proteolysis assay, using resorufin-labeled casein as a substrate. Second, trypsin in the presence and absence of either FSY-NH 2 or LS-NH 2 , was evaluated for its ability to hydrolyze a synthetic peptide substrate, GPNSKGR/SLI-GRLTDPYGGC (P20) representing the cleavage/activation sequence of rat PAR 2 . Third, in the presence and absence of either FSY-NH 2 or LS-NH 2 , the ability of trypsin to cleave and release the N-terminal portion of PAR 2 , that is proximal to the receptor cleavage/activation site, was evaluated in KNRK cells expressing rat PAR 2 with its N-terminal epitope detected with the SLAW antiserum. As shown in Fig. 5 , the rate of proteolysis of resorufin-labeled casein by 10 nM trypsin was unaltered in the presence of either FSY-NH 2 or LS-NH 2 at the same concentrations (200 M) that inhibited PAR 2 activation in the cell and tissue assays (Figs. 1-4) . Also, FSY-NH 2 and LS-NH 2 did not affect trypsin-mediated casein hydrolysis by 2 nM trypsin over a 30-min time period (not shown). As shown in Fig. 6 , brief (3 min) trypsin treatment at room temperature of the peptide (P20) representing the activation/cleavage sequence of rat PAR 2 (GPNSKGR/ SLIGRLDP) followed by quenching of the reaction with soya trypsin inhibitor, yielded a proteolysis product (presumably, SLIGRL. . . ) capable of activating PAR 2 (Fig. 6, A and B) . In keeping with the results of the casein proteolysis experiment, the ability of trypsin (2-10 nM) to cleave P20 to reveal its PAR 2 -activating sequence was not affected in the presence of either FSY-NH 2 or LS-NH 2 at a concentration (200 m) that inhibited trypsin activation of PAR 2 in the calcium-signaling assay. In contrast, the addition of soya trypsin inhibitor to the P20 substrate solution prior to the addition of trypsin completely abolished the release of a PAR 2 activating peptide (no calcium signal, Fig. 6A , third histogram from left; Fig. 6B , top tracing, middle response). Finally, we wanted to investigate at ASPET Journals on July 9, 2017 jpet.aspetjournals.org whether FSY-NH 2 and LS-NH 2 interfered with the ability of trypsin to release the amino terminal SLAW epitope from PAR 2 by proteolytic activation. As shown in Fig. 7 , either in the absence ( Fig. 7A, Trp; Fig. 7D ) or presence of either FSY-NH 2 (Fig. 7A , FSY-NH 2 ϩ Trp; Fig. 7E ) or LS-NH 2 (Fig. 7A , LS-NH 2 ϩTrp; Fig. 7F ), trypsin proteolysis was essentially equally effective in removing the PAR 2 epitope, that is N-terminal to the receptor cleavage/activation site equivalent to P20. The untreated PAR 2 expressing cells ( Fig. 7A, Control; Fig. 7B ) had positive immunoreactivity (granular cell membrane staining) with the SLAW anti-receptor antibody. It was also found that adding a premixed solution of soya trypsin inhibitor and trypsin to the cells prior to the addition of the antibody had no effect on the immunostaining of these cells (data not shown). In addition, immunoreactivity was detected neither when the SLAW antibody was preabsorbed with the receptor-derived peptide immunogen (Fig. 7C ) nor in the empty vector-transfected KNRK cell line (data not shown).
Discussion
The main finding for our study was that the PAR 1 /PAR 2 -related peptides, FSLLRY-NH 2 and LSIGRL-NH 2 , while unable on their own to activate PAR 2 , were able to block the ability of trypsin to do so, either in a PAR 2 calcium signaling Fig. 6 . Proteolytic cleavage by trypsin of a peptide PNSKGR/SLI-GRLDTPYGGC (P20) representing the cleavage/activation domain of rat PAR 2 to yield PAR 2 -activating peptide: lack of effect of FSY-NH 2 and LS-NH 2 and inhibition by soya trypsin inhibitor. As outlined under Materials and Methods, P20 (20 M) was incubated with 2 nM trypsin at room temperature for 3 min. in the absence or presence of FSY-NH 2 (200 M), LS-NH 2 (200 M), or soya trypsin inhibitor (STI 1 g/ml), at which point the reaction was quenched by the addition of added STI (1 g/ml). One minute thereafter, the reaction mixture was added to an indicator cell suspension of fluo-3-loaded rat PAR 2 KNRK cells, and the calcium signal generated was monitored. The calcium signal caused by the release of PAR 2 activating peptide from P20 was compared with the "control" signal generated by trypsin alone. A, histograms show the average calcium signals (Ϯ S.E.M., bars: % control trypsin response; open histogram) caused by the release of a PAR 2 -activating peptide from P20. On its own, P20 did not elicit a calcium response (second histogram from left). Although the addition of STI prior to the addition of trypsin abolished the ability of trypsin to release a PAR 2 -activating peptide from P20 (third histogram from left), the addition of STI after trypsin was combined with P20 did not affect the subsequent calcium signal (fourth histogram from left). Neither FSY-NH 2 nor LS-NH 2 affected the trypsin-mediated release of PAR 2 -activating peptide from P20 to cause a calcium signal (last two histograms on right). B, representative tracings of calcium signals. Each tracing shows the calcium signal generated in fluo-3-loaded rat PAR 2 -KNRK cells by the P20 proteolytic product released by trypsin in the absence or presence of 200 M added peptide (FSY-NH 2 , tracing (b); LS-NH 2 , tracing (c)) or STI (1 g/ml: tracing (a)). The order of addition of P20 peptide, STI, LS-NH 2, FSY-NH 2 , and trypsin are shown at the bottom of each tracing. The control responses to trypsin are shown on the right. jpet.aspetjournals.org assay using PAR 2 -expressing KNRK cells Al-Ani et al., 1999b) or in intact aorta tissue (Fig. 4) wherein proteolytic activation of PAR 2 causes an endothelium-dependent nitric oxide-mediated vasorelaxation (Al-Ani et al., 1995; Saifeddine et al., 1996) . Notwithstanding, neither of these two peptides that antagonize trypsin-mediated PAR 2 activation affected receptor triggering by 100 to 400-fold lower concentrations of the PAR 2 -activating peptide, SLIGRL-NH 2 (Fig. 1, tracing D and Fig. 4) . One possible hypothesis that we considered for the ability of FSY-NH 2 and LS-NH 2 to block trypsin-mediated activation of PAR 2 without affecting activation caused by SL-NH 2 was that the peptides were simply inhibiting directly the proteolytic activity of trypsin, as did STI, to prevent the cleavage/unmasking of the cell-attached tethered ligand (e.g., see Bhattacharya et al., 2001) . However, the results of three independent approaches to test this hypothesis indicated that the peptides, at concentrations that blocked trypsin (2-10 nM)-mediated PAR 2 activation, did not affect trypsin's proteolytic activity in the presence of the peptides at 200 M: 1) the rate of hydrolysis of resorufin-labeled casein was unaffected, 2) cleavage of P20 to yield its PAR 2 -activating sequence was unaffected, and 3) the ability of trypsin acting on receptorexpressing cells to strip the PAR 2 epitope, N-terminal to the receptor cleavage/activation site, was not impeded.
We therefore conclude that a mechanism other than a direct inhibition of trypsin proleolytic activity was responsible for the inhibitory effects of the peptides. This conclusion is supported further by the inability of FSY-NH 2 to inhibit activation of PAR 1 by the serine proteinase thrombin. A working hypothesis we suggest is that although the peptides FSY-NH 2 and LS-NH 2 do not block the ability of trypsin to unmask the tethered receptor-activating ligand sequence, SLIGRL. . . , that they are, nonetheless, able to impede access of the proteolytically revealed tethered ligand to the receptor-activating site, whereas the same peptides do not block access of the soluble receptoractivating peptides to distinct but possibly overlapping receptor activation sites in the extracellular receptor loops. The sites on PAR 2 at which FSY-NH 2 interacts would appear to be receptorspecific, in that the same peptide did not affect the ability of the PAR 1 tethered ligand revealed by thrombin to activate PAR 1 . This possible difference between the docking sites of the soluble and tethered ligand in PAR 2 would be in keeping with data obtained for human PAR 1 (Blackhart et al., 2000) , demonstrating differences between soluble receptor-activating ligands and the protease-revealed tethered ligand for activating selected PAR 1 receptor mutants. Furthermore, our own work with a mutated PAR 2 receptor having arginines substituted for glutamic acid in extracellular loop 2 showed that the trypsin revealed tethered ligand (SLIGRL. . . ) was more effective in activating the receptor than was the comparable soluble receptoractivating ligand, SLIGRL-NH 2 (Al-Ani et al., 1999a) . Taken together, the data obtained by us for PAR 2 (Al-Ani et al., 1999a) and for PAR 1 by Blackhart et al., (2000) point to different receptor activation sites for the tethered and soluble ligands. Such differences, we believe, could conceivably account for the differential ability of FSY-NH 2 and LS-NH 2 to block trypsin but not SL-NH 2 -mediated activation of PAR 2 . Although further work will be required to establish the molecular basis for the suggested differences between the interactions of the tethered and soluble ligands with the receptor, our data obtained with FSY-NH 2 and LS-NH 2 suggest that any future research for putative PAR 2 receptor antagonists should take both potential mechanisms into account, so as to assess receptor activation both by proteolysis with trypsin and by a receptor-activating peptide such as SL-NH 2 .
